Press Releases

Date Title and Summary View
February 17, 2010 Eleven Biotherapeutics Completes $35 Million Series A Funding to Advance Pipeline of Innovative Protein-Based Therapeutics View HTML
September 15, 2010 Eleven Biotherapeutics Named One of the "Fierce 15" Leading Biotech Companies of 2010 View HTML
November 5, 2010 Eleven Biotherapeutics Receives Three Federal Grants to Develop Innovative Protein-Based Therapeutics View HTML
January 6, 2011 Eleven Biotherapeutics Appoints Eric Furfine, Ph.D., to President of Research and Development View HTML
September 22, 2011 Eleven Biotherapeutics Appoints Abbie Celniker, Ph.D., Chief Executive Officer View HTML
April 24, 2012 Eleven Biotherapeutics to Present at the ARVO 2012 Annual Meeting View HTML
May 8, 2012 Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing View HTML
December 19, 2012 Eleven Biotherapeutics Initiates Phase 1b Clinical Study of EBI-005, a Novel, Topically Delivered IL-1 Inhibitor Protein for the Treatment of Dry Eye Disease View HTML
February 19, 2013 Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease View HTML
April 24, 2013 Eleven Biotherapeutics to Present Data on Lead Drug Candidate, EBI-005, at the ARVO 2013 Annual Meeting View HTML